These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Description of hypersensitivity adverse events following administration of heparin that was potentially contaminated with oversulfated chondroitin sulfate in early 2008. McMahon AW; Pratt RG; Hammad TA; Kozlowski S; Zhou E; Lu S; Kulick CG; Mallick T; Dal Pan G Pharmacoepidemiol Drug Saf; 2010 Sep; 19(9):921-33. PubMed ID: 20661880 [TBL] [Abstract][Full Text] [Related]
6. [Contaminated heparins]. Monneret C Ann Pharm Fr; 2008 Aug; 66(4):212-5. PubMed ID: 18847567 [TBL] [Abstract][Full Text] [Related]
7. Contaminated heparin-affected patient plasmas are associated with activated contact systems. Yi Qian ; Jing Pan ; Xiaodong Zhou ; Weiser P; Hong Lu ; Beck AM; Shih FF; Lijuan Zhang Clin Appl Thromb Hemost; 2010 Jun; 16(3):261-5. PubMed ID: 20547554 [No Abstract] [Full Text] [Related]
8. Contaminants in heparins continue to be unfolded. Fareed J; Ahluwalia M; Wahi R; Ramaccioti E; Hoppensteadt D; Bick RL Int Angiol; 2008 Dec; 27(6):457-61. PubMed ID: 19078906 [No Abstract] [Full Text] [Related]
10. Review: contaminants in heparin: review of the literature, molecular profiling, and clinical implications. Ramacciotti E; Clark M; Sadeghi N; Hoppensteadt D; Thethi I; Gomes M; Fareed J Clin Appl Thromb Hemost; 2011 Apr; 17(2):126-35. PubMed ID: 21288929 [TBL] [Abstract][Full Text] [Related]
11. Structure elucidation and biological activity of the oversulfated chondroitin sulfate contaminant in Baxter heparin. McKee J; Bairstow S; Szabo C; Ray J; Wielgos T; Hu P; Chess E; Nordhaus M; Hai T; Campbell J; Donovan S; Viseux N; Riedel N; Cammack J; Johnson R J Clin Pharmacol; 2010 Oct; 50(10):1159-70. PubMed ID: 20147614 [TBL] [Abstract][Full Text] [Related]
12. Contaminants in heparins: are all facts known? Fareed J; Hoppensteadt DA; Ramacciotti E; Hull RD Clin Appl Thromb Hemost; 2010 Jun; 16(3):242-3. PubMed ID: 20547552 [No Abstract] [Full Text] [Related]
13. From crisis to opportunity: a perspective on the heparin crisis. Sasisekharan R; Shriver Z Thromb Haemost; 2009 Nov; 102(5):854-8. PubMed ID: 19888519 [No Abstract] [Full Text] [Related]
14. Analysis of cytokine secretion from lymphocytes of patients with hypersensitivity reactions to contaminated heparins. Martin M; Ott H; Merk HF; Sachs B Br J Dermatol; 2011 Jan; 164(1):68-75. PubMed ID: 20854434 [TBL] [Abstract][Full Text] [Related]
16. Identification of a simple and sensitive microplate method for the detection of oversulfated chondroitin sulfate in heparin products. Bairstow S; McKee J; Nordhaus M; Johnson R Anal Biochem; 2009 May; 388(2):317-21. PubMed ID: 19289093 [TBL] [Abstract][Full Text] [Related]